middle.news
Mesoblast Advances U.S. Launch of Ryoncil® with $160M Boost and Pipeline Milestones
9:40am on Friday 31st of January, 2025 AEDT
•
Biotechnology
Read Story
Mesoblast Advances U.S. Launch of Ryoncil® with $160M Boost and Pipeline Milestones
9:40am on Friday 31st of January, 2025 AEDT
Key Points
Ryoncil® commercial launch planned in the U.S. this quarter targeting pediatric SR-aGvHD
Successful $160 million financing increases cash reserves to approximately $200 million
Robust late-stage pipeline includes Revascor® for heart failure and Rexlemestrocel-L for chronic low back pain
Strategic commercial leadership team and logistics partnerships established for launch
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE